Table 2.

Effect of 14 days of subcutaneous continuous infusion of dalteparin alone, epirubicin alone, and a combination of the two drugs on VEGF-mediated angiogenesis and body weight (BW) at sacrifice

	Vehicle/D + Vehicle/E2	Dalteparin1 + Vehicle/D2	Epirubicin1 + Vehicle/E	Dalteparin + Epirubicin
	Group C I	Group C II	Group T I	Group T II
BW, g	323.30 ± 6.20 (100)	322.00 ± 4.76 (100)	299.60 ± 4.94 (93)	301.40 ± 5.59 (93)
VA3	14.55 ± 2.36 (100)	18.47 ± 2.89 (127)	14.68 ± 2.00 (101)	13.25 ± 2.20 (91)
MVL	1.12 ± 0.08 (100)	1.15 ± 0.07 (103)	0.98 ± 0.08 (88)	0.88 ± 0.06* (79)
TMVL	16.28 ± 2.64 (100)	21.28 ± 3.33 (131)	14.39 ± 1.96 (88)	11.64 ± 1.94** (71)

Values within parenthesis are % of value for CI.

¹Dalteparin at 80 IU/kg/day; epirubicin at 3.0 mg/kg/week.

²Vehicle/D, 0.9% NaCl; Vehicle/E, 0.9% NaCl. Each treatment group comprised 10 animals, with the exception of group T II, which comprised nine animals (one rat was removed due to signs of sickness). There are no statistically significant differences with respect to any variable between groups T I and T II or between groups C I and C II. Data shown are mean ± SEM.

³VA, vascularized area, a measure of microvessel spatial extension; MVL, microvascular length, a composite measurement of microvessel density; TMVL, total microvascular length (VA × MVL).

^*p ≤ 0.02 compared with C II, p ≤ 0.01 compared with [C I + C II];

^**p ≤ 0.04 compared with C II, p ≤ 0.05 compared with [C I + C II].